Reports
Sale
Autism Spectrum Disorders Market Size, Share, Trends, Growth: By Type: Autistic Disorder, Asperger Syndrome, Pervasive Development Disorder (PDD), Others; By Treatment Type: Behavioural Approaches, Early Intervention, Medication, Others; By End User: Hospitals, Others; Regional Analysis; Supplier Landscape; 2024-2032
Autism Spectrum Disorders Market Outlook
The autism spectrum disorders market size is expected to grow at a CAGR of 5.5% during the forecast period of 2024-2032, driven by the increasing incidence of the condition and rising research activities to combat comorbidities associated with the condition across the 8 major markets.
Autism Spectrum Disorders Market Overview
Autism spectrum disorder (ASD) is a neurological disorder affecting a person's ability to interact, communicate, behave, and learn. It is termed as a ‘developmental disorder’ as the symptoms appear within the first two years of life. Diagnosis is generally based on a child’s behavior. Most children are diagnosed at the age of 4. Approximately 1 in 36 (around 2.8%) children have been identified with the condition, with boys being more susceptible to developing the disease than girls. The male to female of disease prevalence is 4:1.
40% of the children diagnosed with autism are nonverbal, while 44% of them have average or above average intellectual ability and 31% may have an intellectual disability. It may also affect a child’s ability to move and pay attention. The prevalence rates vary across different regions, with some areas having higher prevalence rates. For instance, California has an incidence of 1 in 26 patients, while South Korea has 1 in 38 patients affected by autism. The autism spectrum disorders market demand is driven by the increasing prevalence of the disease, as the cases reported in 2023 saw a surge by 317% compared to 2000. The prevalence rates in adults are comparatively lower than children. In the United States, approximately 2.2% of the adults are autistic.
Advent of Mobile Applications to Manage Autism
In May 2023, BlueSprig Pediatrics , a United States based prominent autism therapy provider launched Attend Behavior App to provide individualized and effective behavioral strategies for children suffering from autism, ADHD, and other behavioral conditions. With the app, parents can receive real time support and guidance to help their children. The rising integration and utilization of mobile apps is expected to benefit the autism spectrum disorders market growth in the forecast period.
Increased Collaborations to Develop Efficient Treatment
In June 2023, PaxMedica , Inc. entered a strategic partnership with PoloMar Health to investigate the use of emodin as a potential treatment for treating autism spectrum disorder. Emodin is a naturally occurring substance found in several plants and is an orally bioavailable selective P2X7 inhibitor, currently used in multiple nutritional supplements. PoloMar Health is also working with the BRAIN Foundation as a part of this initiative. The rising collaborations amongst companies to deliver effective and efficient solutions is anticipated to bolster the autism spectrum disorders market share.
Emphasis on Treating Comorbidities of Autism
38 % of the patients with ASD experience seizures while 40% suffer from anxiety. Sleep issues affect 53% of the people. The autism spectrum disorders market value is further boosted by the application of new technologies to address rare comorbidities associated with the disease. In February 2023, a group of Northwestern researchers devised a new therapy to treat Phelan-McDermid syndrome , which is a rare subtype of ASD. The new drug is designed to address cognitive function, and motor behavior deficiencies among others. Moreover, there is a key focus on expanding the existing treatment options for adults as well.
Growing Prevalence for Alternative Therapies
One treatment cannot help all the patients, therefore, there has been increasing importance on developing new therapeutics that address a wider spectrum of symptoms. Behavior therapy, speech-language therapy, physical therapy, and occupational therapy are common treatment methods in the market. Applied behavior analysis is a prominent behavioral treatment with two discrete trial training and pivotal response training as major categories. In addition, the researchers are continuously working to identify new potential treatments.
Autism Spectrum Disorders Market Segmentation
Market Breakup by Type
- Autistic Disorder
- Asperger Syndrome
- Pervasive development disorder (PDD)
- Other
Market Breakup by Treatment Type
- Behavioural Approaches
- Early Intervention
- Medication
- Other
Market Breakup by End User
- Hospitals
- Education Counsellor Center
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Autism Spectrum Disorders Market Regional Analysis
The United States is expected to lead the autism spectrum disorders market share, owing to the high prevalence of the disease in the region. The market is further driven by the application of novel technologies to cater to the unmet needs of patients. In December 2023, United States based NeuroQure , an aspiring biotech startup focusing on gene therapy for neurocognitive disorders acquired exclusive rights to license a patent portfolio from CART (UC Irvine Center for Autism Research and Translation) with an investment of USD 14 million. The acquisition aims to deliver functional biomarkers to facilitate early diagnosis of the condition in newborns to enable early intervention.
Autism Spectrum Disorders Market: Competitor Landscape
In December 2023, Harmony Biosciences Holdings, Inc . acquired Zynerba Pharmaceuticals, Inc. with a USD 60 million deal. Harmony, a pioneering pharmaceutical company that aims at commercializing and developing innovative therapies for rare neurological diseases envisions to expand their product portfolio with multiple assets that address the unmet needs of patients suffering from autism. This acquisition is expected to treat the symptoms of Fragile X syndrome as well. The increasing merger and acquisition activities are one of the prominent market trends, projected to boost the market value in the forecast period.
The key features of the autism spectrum disorders market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Abbvie Inc
- Jazz Pharmaceuticals
- dfusion inc.
- Cognoa Inc
- Novartis AG
- Johnson & Johnson
- Curemark LLC
- EarliTec Diagnostics Inc
- Bristol Myers Squibb Co.
- Axial therapeutics
- Q BioMed Inc.
- PaxMedica.
- Otsuka Pharmaceutica
- Stalicla
- Zynerba Pharmaceuticals
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Treatment Type |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Austin Spectrum Market Overview – 8 Major Markets
3.1 Austin Spectrum Disorder Market Historical Value (2017-2023)
3.2 Austin Spectrum Disorder Market Forecast Value (2024-2032)
4 Austin Spectrum Diseases Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Autism Spectrum Disorders Epidemiology Analysis – 8 Major Markets
6.1 8MM Epidemiology Scenario Overview (2017-2032)
6.2 United States Autism Spectrum Disorders Epidemiology Forecast (2017-2032)
6.3 EU-4 and United Kingdom Autism Spectrum Disorders Epidemiology Forecast (2017-2032)
6.3.1 Germany Autism Spectrum Disorders Epidemiology Forecast (2017-2032)
6.3.2 France Autism Spectrum Disorders Epidemiology Forecast (2017-2032)
6.3.3 Italy Autism Spectrum Disorders Epidemiology Forecast (2017-2032)
6.3.4 Spain Autism Spectrum Disorders Epidemiology Forecast (2017-2032)
6.3.5 United Kingdom Autism Spectrum Disorders Epidemiology Forecast (2017-2032)
6.4 Japan Autism Spectrum Disorders Epidemiology Forecast (2017-2032)
6.5 India Autism Spectrum Disorders Epidemiology Scenario and Forecast (2017-2032)
7 Autism Spectrum Disorders Market Landscape – 8 Major Markets
7.1 Autism Spectrum Disorders: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Autism Spectrum Disorders: Product Landscape
7.2.1 Analysis by Product Type
7.2.2 Analysis by Treatment Type
7.2.3 Analysis by Route of Administration
8 Autism Spectrum Disorders Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Autism Spectrum Disorders Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.2.1 Strengths
10.2.2 Weaknesses
10.2.3 Opportunities
10.2.4 Threats
10.3 Porter’s Five Forces Model
10.3.1 Bargaining Power of Suppliers
10.3.2 Bargaining Power of Buyers
10.3.3 Threat of New Entrants
10.3.4 Threat of Substitutes
10.3.5 Degree of Rivalry
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Autism Spectrum Disorders Market Segmentation (2017-2032) – 8 Major Markets
11.1 Autism Spectrum Disorders Market (2017-2032) by Type
11.1.1 Market Overview
11.1.2 Autistic Disorder
11.1.3 Asperger Syndrome
11.1.4 Pervasive development disorder (PDD)
11.1.5 Others
11.2 Autism Spectrum Disorders Market (2017-2032) by Treatment Type
11.2.1 Market Overview
11.2.2 Behavioural Approaches
11.2.3 Early Intervention
11.2.4 Medication
11.2.5 Others
11.3 Autism Spectrum Disorders Market (2017-2032) by End User
11.3.1 Market Overview
11.3.2 Hospitals
11.3.3 Education Counsellor Center
11.3.4 Others
11.4 Autism Spectrum Disorders Market (2017-2032) by Region
11.4.1 Market Overview
11.4.2 United States
11.4.3 EU-4 and the United Kingdom
11.4.3.1 Germany
11.4.3.2 France
11.4.3.3 Italy
11.4.3.4 Spain
11.4.3.5 United Kingdom
11.5 Japan
11.6 India
12 United States Autism Spectrum Disorders Market (2017-2032)
12.1 United States Autism Spectrum Disorders Market Historical Value (2017-2023)
12.2 United States Autism Spectrum Disorders Market Forecast Value (2024-2032)
12.3 United States Autism Spectrum Disorders Market (2017-2032) by Type
12.3.1 Market Overview
12.3.2 Autistic Disorder
12.3.3 Asperger Syndrome
12.3.4 Pervasive development disorder (PDD)
12.3.5 Other
12.4 United States Autism Spectrum Disorders Market (2017-2032) by Treatment Type
12.4.1 Market Overview
12.4.2 Behavioural Approaches
12.4.3 Early Intervention
12.4.4 Medication
12.4.5 Other
13 EU-4 and United Kingdom Autism Spectrum Disorders Market
13.1 EU-4 and United Kingdom Autism Spectrum Disorders Market Historical Value (2017-2023)
13.2 EU-4 and United Kingdom Autism Spectrum Disorders Market Forecast Value (2024-2032)
13.2.1 EU-4 and United Kingdom Autism Spectrum Disorders Market (2017-2032) by Type
13.2.1.1 Market Overview
13.2.1.2 Autistic Disorder
13.2.1.3 Asperger Syndrome
13.2.1.4 Pervasive development disorder (PDD)
13.2.1.5 Other
13.2.2 EU-4 and United Kingdom Autism Spectrum Disorders Market (2017-2032) by Treatment Type
13.2.2.1 Market Overview
13.2.2.2 Behavioural Approaches
13.2.2.3 Early Intervention
13.2.2.4 Medication
13.2.2.5 Other
14 Japan Autism Spectrum Disorders Market
14.1 Japan Autism Spectrum Disorders Market Historical Value (2017-2023)
14.2 Japan Autism Spectrum Disorders Market Forecast Value (2024-2032)
14.2.1 Japan Autism Spectrum Disorders Market (2017-2032) by Type
14.2.1.1 Market Overview
14.2.1.2 Autistic Disorder
14.2.1.3 Asperger Syndrome
14.2.1.4 Pervasive development disorder (PDD)
14.2.1.5 Other
14.2.2 Japan Autism Spectrum Disorders Market (2017-2032) by Treatment Type
14.2.2.1 Market Overview
14.2.2.2 Behavioural Approaches
14.2.2.3 Early Intervention
14.2.2.4 Medication
14.2.2.5 Other
15 India Autism Spectrum Disorders Market
15.1 India Autism Spectrum Disorders Market Historical Value (2017-2023)
15.2 India Autism Spectrum Disorders Market Forecast Value (2024-2032)
15.2.1 India Autism Spectrum Disorders Market (2017-2032) by Type
15.2.1.1 Market Overview
15.2.1.2 Autistic Disorder
15.2.1.3 Asperger Syndrome
15.2.1.4 Pervasive development disorder (PDD)
15.2.1.5 Other
15.2.2 India Autism Spectrum Disorders Market (2017-2032) by Treatment Type
15.2.2.1 Market Overview
15.2.2.2 Behavioural Approaches
15.2.2.3 Early Intervention
15.2.2.4 Medication
15.2.2.5 Other
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 Abbvie Inc
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisitions
22.1.5 Certifications
22.2 Jazz Pharmaceuticals
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisitions
22.2.5 Certifications
22.3 dfusion inc.
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisitions
22.3.5 Certifications
22.4 Cognoa Inc
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisitions
22.4.5 Certifications
22.5 Novartis AG
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisitions
22.5.5 Certifications
22.6 Johnson & Johnson
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisitions
22.6.5 Certifications
22.7 Curemark LLC
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisitions
22.7.5 Certifications
22.8 EarliTec Diagnostics Inc
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisitions
22.8.5 Certifications
22.9 Bristol Myers Squibb Co.
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisitions
22.9.5 Certifications
22.10 Axial therapeutics
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisitions
22.10.5 Certifications
22.11 Q BioMed Inc.
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisitions
22.11.5 Certifications
22.12 PaxMedica.
22.12.1 Financial Analysis
22.12.2 Product Portfolio
22.12.3 Demographic Reach and Achievements
22.12.4 Mergers and Acquisitions
22.12.5 Certifications
22.13 Otsuka Pharmaceutica
22.13.1 Financial Analysis
22.13.2 Product Portfolio
22.13.3 Demographic Reach and Achievements
22.13.4 Mergers and Acquisitions
22.13.5 Certifications
22.14 Stalicla
22.14.1 Financial Analysis
22.14.2 Product Portfolio
22.14.3 Demographic Reach and Achievements
22.14.4 Mergers and Acquisitions
22.14.5 Certifications
22.15 Zynerba Pharmaceuticals
22.15.1 Financial Analysis
22.15.2 Product Portfolio
22.15.3 Demographic Reach and Achievements
22.15.4 Mergers and Acquisitions
22.15.5 Certifications
List not exhaustive
23 Autism Spectrum Disorders - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 5.5% during the forecast period of 2024-2032, driven by the increasing incidence of the condition and heightened emphasis on treating comorbidities related to autism.
The market demand is driven by the increasing collaborations and acquisitions amongst key healthcare players along with rising preference for alternative therapies to manage the condition.
The major market trend involves the advent of mobile applications to offer efficient and real time guidance to patients. In May 2023, BlueSprig Pediatrics, an autism therapy provider based out of United States launched Attend Behavior App to provide individualized and effective behavioural strategies for children suffering from autism, ADHD, and other behavioural conditions.
Based on treatment types, the market is divided into behavioral approaches, early intervention, medication and other.
Major end users include hospitals, education counsellor center, and others.
It includes autistic disorder, Asperger syndrome, pervasive development disorder (PDD) and other.
The major regions of the market include the United States, Japan, India, and EU-4 which is segmented into Germany, France, Italy, Spain, United Kingdom and the United Kingdom.
Key players involved in the market are Abbvie Inc., Jazz Pharmaceuticals, dfusion inc., Cognoa Inc., Novartis AG, Johnson & Johnson, Curemark LLC, EarliTec Diagnostics Inc., Bristol Myers Squibb Co., Axial therapeutics, Q BioMed Inc., PaxMedica, Otsuka Pharmaceutica, Stalicla and Zynerba Pharmaceuticals.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER